Varying effects of tyrosine kinase inhibitors on platelet function—A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?

Since their introduction, tyrosine kinase inhibitors (TKIs, eg, imatinib, nilotinib, dasatinib, bosutinib, ponatinib) have revolutionized the treatment of chronic myeloid leukemia (CML). However, long‐term treatment with TKIs is associated with serious adverse events including both bleeding and thro...

Descripción completa

Detalles Bibliográficos
Autores principales: Deb, Suryyani, Boknäs, Niklas, Sjöström, Clara, Tharmakulanathan, Anjana, Lotfi, Kourosh, Ramström, Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943147/
https://www.ncbi.nlm.nih.gov/pubmed/31714021
http://dx.doi.org/10.1002/cam4.2687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943147/
https://www.ncbi.nlm.nih.gov/pubmed/31714021
http://dx.doi.org/10.1002/cam4.2687

Ejemplares similares